Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
The discussants envisioned the future Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) landscape. Dr Jabbour foresees identifying patients still needing intensive therapy, better tyrosine kinase inhibitors, preventing central nervous system relapse, and potentially stopping therapy after several years via measurable residual disease monitoring. Chemo-free approaches are imminent. Dr McCloskey concurred, highlighting community implementation challenges but tremendous improvements for quality of life. Dr Abbas contrasted historic posttransplant outcomes with far superior responses from today’s oral targeted therapy. Further optimizing initial Ph+ ALL treatment stands to enrich more patient lives. Ongoing advances promise even brighter futures.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More